Last Updated : November 10, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Vesicare | Solifenacin succinate | Bladder, overactive | Do not list | Complete | ||
Vesicare | Solifenacin succinate | Bladder, overactive | List with clinical criteria and/or conditions | Complete | ||
VesiFlow | Solifenacin succinate / tamsulosin hydrochloride | Benign prostatic hyperplasia | Withdrawn | |||
VFEND | Voriconazole | Aspergillosis, Invasive | Withdrawn | |||
VFEND | Voriconazole | Aspergillosis, Invasive | List with clinical criteria and/or conditions | Complete | ||
VFEND | Voriconazole | Candidemia | List with clinical criteria and/or conditions | Complete | ||
Viacoram | perindopril arginine / amlodipine | Hypertension, essential | Reimburse with clinical criteria and/or conditions | Complete | ||
Viberzi | eluxadoline | Irritable bowel syndrome with diarrhea | Do not reimburse | Complete | ||
Victoza | liraglutide | Diabetes Mellitus, Type 2 (pediatric) | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | ||
Victoza | Liraglutide | Diabetes mellitus, Type 2 | Do not list | Complete | ||
Victoza | Liraglutide | Diabetes Mellitus, Type 2 | Withdrawn | |||
Victrelis | Boceprevir | Hepatitis C, chronic | List with clinical criteria and/or conditions | Complete | ||
Victrelis | Boceprevir | Hepatitis C, chronic | List with criteria/condition | Complete | ||
Victrelis | Boceprevir | Hepatitis C, chronic | List with criteria/condition | Complete | ||
Viibryd | vilazodone | Depression, Major depressive disorder | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | ||
Vimizim | Elosulfase alfa | Mucopolysaccharidosis IVA (Morquio A syndrome) | Do not list | Complete | ||
Vimizim | Elosulfase alfa | Mucopolysaccharidosis IVA (Morquio A syndrome) | Reimburse with clinical criteria and/or conditions | Complete | ||
Vimpat | Lacosamide | Epilepsy, partial onset seizures | List with clinical criteria and/or conditions | Complete | ||
Viread | Tenofovir disoproxil fumarate | HIV infection | Do not list | Complete | ||
Viread | Tenofovir disoproxil fumarate | HIV infection | List with clinical criteria and/or conditions | Complete | ||
Viread | Tenofovir disoproxil fumarate | HIV infection | N/A | Complete | ||
Viread | Tenofovir disoproxil fumarate | Hepatitis B (chronic) | List with clinical criteria and/or conditions | Complete | ||
Visanne | Dienogest | Pain, pelvic pain associated with endometriosis | List with clinical criteria and/or conditions | Complete | ||
Vitrakvi | Larotrectinib | NTRKplus solid tumours | Do not reimburse | Complete | ||
Vitrakvi | larotrectinib | Solid tumours with NTRK gene fusion | Reimburse with clinical criteria and/or conditions | Complete |